We’re an international venture capital firm that has helped build over 300 companies in the last 25 years.
Over the last decade our portfolio companies have completed more than 30 IPOs on twelve different stock exchanges.
|
“Our company developed from a start-up to a successful public company with over 500 employees and $80 million in annual revenues by following a bold, innovative strategy. This strategy was developed with valuable insight from Atlas Venture, and key to the strategy was a major contract with Glaxo SmithKline, which was facilitated by Atlas' contacts there.”
George Scangos Ph.D., President and CEOExelixis |